Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.
Semaglutide doesn’t just shine in controlled clinical trials—it’s now showing real impact in the “messy” real world. A new multicenter study from Pakistan tracked 217 adults with type 2 diabetes over 30 weeks as they started using biosynthetic semaglutide. The results: strong improvements across the board.
Diabetes Obes Metab
by Hussain A, Wahab MU, Qureshi S et al.
“Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Hussain A(1), Wahab MU(2), Qureshi S(3), Raja UY(4), Munir A(5), Gardezi S(6), Iqbal M(3), Afzal B(7), Butt MD(8), Ong SC(8). Author information: (1)North-West General Hospital, Peshawar, Pakistan. (2)Umar Diabetes and Foot Care Centre and Umar Diabetes Foundation, Islamabad, Pakistan. (3)Department of Medicine, Center for Diabetes and Liver Disease, Islamabad, Pakistan. (4)Shifa International Hospitals Ltd., Islamabad, Pakistan. (5)Omer Hospital, Lahore, Pakistan. (6)City Hospital, Multan, Pakistan. (7)Mukhtar A Sheikh Hospital, Multan, Pakistan. (8)School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Penang, Malaysia. AIMS: To evaluate the real-world effectiveness, safety and patient-reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost-constrained setting. METHODS: This 30-week, prospective, multicentre, non-interventional study enrolled adults with T2DM initiating biosynthetic semaglutide. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, waist circumference, patient-reported outcomes (DTSQs and SF-36v2) and safety. RESULTS: Among 217 patients, mean HbA1c decreased from 9.27% to 7.41% at EOS (-1.86%; p < 0.001). At EOS, 76.6% achieved HbA1c < 8.0% and 38.7% achieved < 7.0%. Mean body weight decreased by -7.84 kg (p < 0.001), with 76.5% achieving ≥ 5% weight loss. Significant reductions were also observed in body mass index and waist circumference. Treatment satisfaction and physical quality of life improved significantly. Adverse events were predominantly non-serious and gastrointestinal. No severe hypoglycaemic episodes occurred. CONCLUSIONS: In routine clinical practice, biosynthetic semaglutide was associated with clinically meaningful improvements in glycaemic control, body weight and physical quality of life. The safety profile remained consistent with established semaglutide therapy. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12625000610437. © 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”
Let’s cut to the chase. Average HbA1c dropped from 9.27% to 7.41%. That’s nearly a two-point dip, which is huge for anyone who follows glycemic control. Over three-quarters of participants hit an HbA1c below 8%, and almost 40% landed under 7%. This isn’t just a numbers game—these are targets most diabetes guidelines push for.
Weight loss was just as impressive. Average body weight fell by almost 8 kg, with 76.5% of patients dropping at least 5% of their starting weight. Waist circumference and BMI both moved in the right direction too.
Researchers didn’t just measure numbers. They checked in on patient satisfaction and quality of life, both of which climbed during the study. That matters when you’re thinking long-term research protocols and adherence.
Key takeaway: The safety profile looked solid. No severe hypoglycemia. Most side effects were mild and related to the gut—nothing unexpected for semaglutide.
For anyone sourcing biosynthetic peptides for research, this kind of real-world evidence matters. The study shows semaglutide’s effectiveness and safety hold up even outside the ivory tower. Looking for a reputable supplier? Check the vendor directory.
Bottom line: Semaglutide continues to deliver where it counts—in real research settings, not just perfect lab conditions.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.